ACADIA Pharmaceutical Gets Equity Injection

San Diego-based Acadia Pharmaceuticals has received a new, $10M equity investment from its partner, Separacor. Acadia said that Sepracor completed the purchase of $10M of Acadia common stock, and issued 813,393 shares of ACADIA common stock as a part of the transaction. Acadia is developing treatments for central nervous system (CNS) disorders. The firms are collaborating on combining Acadia's compounds with Sepracor's Lunesta sleep aid product. More information »